ClinicalTrials.gg

Program

PF-08653945

A development code.

In Pfizer's pipeline, Amylin analog (with dual amylin and calcitonin receptor activity). Its studies are mostly in Obesity, led by Pfizer.

Furthest: phase 2, since May 4, 20262 company-led studies, 2 open or runningNext primary completion: Jan 13, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer22 open or runningphase 2since May 4, 2026May 4, 2026Jan 13, 2027phase 1 · NCT07725809
  • Named in Pfizer’s own pipeline as PF-08653945, phase 2, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 4, 2026First study: phase 2 study in OverweightFirst studyNCT07575932 · 940 enrolled · United States, Canada
  2. Jul 21, 2026Phase 1 study in OverweightNCT07725809 · 57 enrolled · Belgium

Ahead

  1. Jan 13, 2027Primary completion: phase 1 study in OverweightNCT07725809
  2. Aug 4, 2027Primary completion: phase 2 study in OverweightNCT07575932

TargetBeta

“Amylin analog (with dual amylin and calcitonin receptor activity)”the company's pipeline, read by Claude · source

Other programs on CALCR

ProgramCompanyFurthest phaseStudies
cagrilintideNovo Nordiskphase 350
zenagamtideNovo Nordiskphase 335
petrelintideruleZealand Pharmaphase 311
ABBV-295AbbViephase 25
GUB014295AbbViephase 11
CagriSema ANovo Nordiskphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07725809Overweight · Belgium1Active, not recruitingJan 13, 202757
NCT07575932Overweight · United States, Canada2Active, not recruitingAug 4, 2027940

How it is read

Names in the registry

  • “PF-08653945”, 2 entries

Codes read as this program: PF08653945.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.